Patients using older GLP-1 medications like Byetta are increasingly transitioning to newer therapies such as Wegovy and Zepbound. Here’s how the switching process works, why dose escalation matters, and what clinicians consider when choosing between semaglutide and tirzepatide.
As tirzepatide and semaglutide drive larger weight-loss results, questions about muscle preservation and body composition are becoming increasingly important in obesity medicine.
A major clinical trial found that tirzepatide produced greater average weight loss than semaglutide over 72 weeks. Here’s what researchers believe explains the difference between these two leading obesity medications.
New clinical trial data show that Zepbound users lost significantly more weight than Wegovy users over 72 weeks. Here’s how tirzepatide and semaglutide compare in effectiveness, side effects, cardiovascular benefits, and obesity treatment outcomes.
Rapid weight loss from GLP-1 medications can accelerate facial aging through volume depletion and collagen loss. This in-depth guide compares Sculptra vs. Radiesse for restoring facial structure, tightening skin, and treating “Ozempic Face.”
GLP-1 drugs have transformed obesity treatment, with tirzepatide now leading in effectiveness. Here’s what the latest 2026 evidence reveals about safety, results, and future therapies.